Algert Global’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-84,883
| Closed | -$2M | – | 1318 |
|
|
2023
Q4 | $2M | Sell |
84,883
-8,003
| -9% | -$143K | 0.08% | 417 |
|
|
2023
Q3 | $1.38M | Buy |
+92,886
| New | +$1.23M | 0.07% | 486 |
|
|
2023
Q2 | – | Sell |
-15,080
| Closed | -$131K | – | 1314 |
|
|
2023
Q1 | $131K | Sell |
15,080
-38,470
| -72% | -$308K | 0.01% | 1066 |
|
|
2022
Q4 | $336K | Sell |
53,550
-5,190
| -9% | -$19.7K | 0.02% | 911 |
|
|
2022
Q3 | $206K | Sell |
58,740
-38,854
| -40% | -$140K | 0.01% | 1035 |
|
|
2022
Q2 | $288K | Buy |
97,594
+49,600
| +103% | +$118K | 0.02% | 929 |
|
|
2022
Q1 | $149K | Buy |
47,994
+860
| +2% | +$2.71K | 0.01% | 1075 |
|
|
2021
Q4 | $159K | Buy |
47,134
+25,450
| +117% | +$96.6K | 0.02% | 883 |
|
|
2021
Q3 | $79K | Buy |
+21,684
| New | +$85.4K | 0.01% | 981 |
|
|
2021
Q2 | – | Sell |
-31,470
| Closed | -$143K | – | 554 |
|
|
2021
Q1 | $143K | Buy |
31,470
+19,380
| +160% | +$104K | 0.05% | 392 |
|
|
2020
Q4 | $69K | Sell |
12,090
-21,740
| -64% | -$165K | 0.02% | 389 |
|
|
2020
Q3 | $245K | Sell |
33,830
-45,520
| -57% | -$243K | 0.08% | 290 |
|
|
2020
Q2 | $277K | Buy |
+79,350
| New | +$229K | 0.09% | 285 |
|
Other funds holding CBAY
Algert Global's CBAY Position: Q1 2024 in Review
Algert Global sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 84,883 shares — an estimated $2M sold.
Algert Global first reported a position in CBAY in Q2 2020 and held it in 13 quarters. The position peaked at $2M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Algert Global reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Algert Global sold 84,883 Cymabay Therapeutics shares in Q1 2024, an estimated $2M.
- Algert Global first reported a position in Cymabay Therapeutics in Q2 2020 and held it in 13 quarters.
- Algert Global's Cymabay Therapeutics position peaked at $2M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Algert Global's 13F filing for Q1 2024, filed 15 May 2024.